Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...

Please provide your email address to receive an email when new articles are posted on . Staging from prostate-specific membrane androgen PET/CT had a significant association with PFS. Whole pelvis ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...

Examples include (i) “low” PSMA uptake in a slightly enlarged lymph node (s) in men with newly diagnosed or recurrent ...

Risk factors for worse prognosis after prostate cancer biochemical recurrence (BCR) included clinicopathologic variables, PSA, and shorter time to BCR among prostatectomy patients. Among patients ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...